Table 6 Evaluation of Treatment Effectiveness
Group A | Group B | |
|---|---|---|
No. of patients | 18 | 19 |
Clinical scores (\(\overline{x }\)± SD) | ||
At the primary diagnosis | 1.22 ± 0.547 | 14.79 ± 1 .686 |
After the initial treatment | 0.00 ± 0.00 | 1.00 ± 1.563 |
p value | < 0.01 | < 0.01 |
Disease status | ||
NAD/better/stable | 18 (100%) | 19 (100%) |
Progressive | 0 | 0 |
Subsistence analysis | ||
4 -year EFS (%) | 94.4% | 89.5% |
Event (diabetes insipidus) | 1 (5.5%) | 2 (10.5%) |
Event’s time, M | 4.54 | 18.64 / 20.25 |
4 -year OS (%) | 100% | 100% |
Treatment-related adverse effects (Grade III or above of CTCAE 4.0) | ||
Hair loss | 5 (27.8%) | 18 (95%) |
Fever | 0 | 2 (10.5%) |
Intestinal obstruction | 1 (5.6%) | 0 |
Hematological damage | ||
Anemia | 0 | 12 (63.2%) |
Thrombocytopenia | 0 | 14 (73.7%) |
Cardiac dysfunction | 0 | 0 |
Hepatic dysfunction | 0 | 0 |